Clinical Trial Update: A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing SB15, a proposed aflibercept biosimilar, to Eylea in neovascular age-related macular degeneration has completed with results posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• EYLEA (Aflibercept)
• SB15 (aflibercept biosimilar)

Snippet

Sponsor: Samsung Bioepis Co., Ltd. | Conditions: Neovascular Age-related Macular Degeneration | Phase 3 | Status: COMPLETED | Results posted: 2024-02-05